

LSI USA '22

EMERGING MEDTECH SUMMIT



Embodly is the soft tissue healing company.

- Historical focus had been on “mechanical strength” augmentation, not biological.

*Formative cadaveric or synthetic products lack appropriate **combination of biologic collagen chemistry, microarchitecture & structural integrity for tendon repair***

- Funded by DARPA and AFWERX with \$22 million to develop collagen-based implants for soft tissue repair and augmentation.
- Launched Tapestry Biointegrative Implant in 2021. Launching TAPESTRY RC in arthroscopic RC repair in Q2.
- Launching MICROBRAID in Q1 2023.


 **TAPESTRY**[®]
Biointegrative Implant

 **TAPESTRY**[®]
RC

 **MICROBRAID**[™]

EMBODY

Platforms Extend to All Major Sports Med Segments



An Exceptional Team to Deliver Commercial Results



Jeff Conroy
CEO



Tim Meyers
CFO



Rob Brown
CCO



Christy Nelson
VP, Manufacturing



John Rizzo
VP, Sales



Brianna Schehr
Dir, Clinical & Regulatory



Caitlin Harclerode
Dir, Product Marketing



Vicki Phillos
Dir, Commercial Ops



Matt Havener
Dir, Product Development

Clinical Advisors and Faculty

Shoulder

- *Kevin Bonner, MD*, Jordan-Young Institute
- *Brandon Bryant, MD*, Inova Sports Medicine, Washington NFL Team & Nationals Team Surgeon
- *Nick Sgaglione, MD*, Northwell Health
- *Louis McIntyre, MD*, Northwell Health
- *Sean Churchill, MD*, Aurora Health Center
- *Chris Jones, MD*, Colorado Springs Orthopedic
- *Sam Harmsen, MD*, TOCA
- *Kyle McClintock, MD*, Sutter Health, CORE Inst.
- *Amit Nathani, MD*, The Spine & Orthopedic Ctr CA

Hip

- *W. Kelton Vasileff, MD*, Ohio State University Medical Ctr
- *John Ryan, MD*, Ohio State University Medical Ctr

Foot & Ankle


- *Sam Adams, MD*, Duke Orthopedics, Head of F & A Research
- *Sheldon Lin, MD*, Rutgers-NJMS, Head of Orthopedic Research
- *Bill Simon, DPM*, Atlantic Foot & Ankle Center
- *Alan Ng, DPM*, FACFAS Denver, CO
- *Eric Giza, MD*, UC Davis
- *Kent Ellington, MD*, OrthoCarolina, NC

Sports Med (Knee)

- *Greg DiFelice, MD*, Hospital for Special Surgery
- *Kevin Bonner, MD*, Jordan-Young Institute

Orthopedic Research


- *Steven Arnoczky, DVM*, Michigan State University



TAPESTRY Optimized Physio-Chemistry for Tendon

The TAPESTRY Biointegrative Implant is a bioengineered implant combining Type 1 Bovine collagen chemistry with a highly aligned & highly porous architecture

- Bioengineered micro-architecture & chemistry specifically designed for tendon repair.
 - Unaligned outer surface for isotropic suture retention strength and structural integrity
 - Highly aligned and consistent microarchitecture mimics native tendon
- Highly porous (>90%) to encourage cell and fluid infiltration
- Broad range of sizes & shapes: 20x30mm up to 70x50mm
- Room Temperature Storage, no refrigeration required
- FDA Clearance October 9, 2020 (K201572)
 - Indicated for the management and protection of tendon injuries"Preclinical studies of TAPESTRY® showed dense collagenous fibrous connective tissue ingrowth into and around the scaffolding"



TAPESTRY Mechanism of Action


A collagen-based co-polymer with highly aligned, cell infiltration friendly microstructure and controlled degradation profile, tailored fiber diameter, specific porosity/void up to 100 μm .

Patented Collagen Co-polymer


Patented Physio-Chemistry

Bioengineered 3D Micro-architecture


Unique Cellular Micro-environment




Early cell infiltration, attachment, and elongation



New collagen deposition and biointegration at 4wks




Incorporation into the native tissue 26wks




Induction of new, dense, collagenous tendon-like tissue @ 26 – 52wks

Neighboring Native Achilles




Superior Micro-Architecture for Tendon Healing¹


TAPESTRY



Reconstituted Collagen




Acellular Dermis



TAPESTRY is significantly more porous and ordered than conventional biomaterials and is an analog to native tendon structure

Ultrasound Imaging at 6-Months



KEY FINDINGS

- Tendon thickness: 0.5 cm
- Tendon width: 3.1 cm
- Tendon echotexture: "Normal fibrillar echogenic tendon architecture without evidence of tendinosis."
- Tendon integrity: "Intact"
- Other: "The collagen scaffold is not directly visualized suggesting complete integration or resorption. No anterior glenohumeral joint effusion or distention of the subcoracoid bursa."

Conclusion: "Intact subscapularis tendon without evidence of tendinosis or tear."



- Subscapularis Patient Series (n=5-15), with plans to expand to multi-center study & registry creation. Patients undergoing anatomic shoulder arthroplasty for primary glenohumeral osteoarthritis.
- 6 month post-op Ultrasound Evaluation w/fellowship-trained MSK radiologist (SSc integrity, tendon thickness, collagen architecture, graft integration)
- No complications observed (no aseptic bursitis, infection, SSc ruptures).

LifeNet Exhibit 2012

Embod, et al. v. LifeNet, IPR2025-00248

Page 8

Unparalleled Clinical Applications to Date...






Instrumented Delivery & Fixation Solution



TAPESTRY RCR Addressable Procedures

Grade III Partial and Full Tears = **640k Annually**



- 510(k) Clearance for broad indication of **“Management and protection of tendon injuries”**
- Grade III partial and Full Thickness tears = 80% of mkt
- Severe Tendinosis, failed conservative treatment

TAPESTRY RC System: Streamlined Delivery & Fixation

Simple. Controlled. Versatile. Efficient.



Implant Delivery

- Simple & low-cost design.
- Introducer pre-loaded with implant
 - Sizes: 20x30mm, 30x30mm, 40x30mm
- Highly controlled, single handed placement & operation
- Accommodates surgeon approach preference (lateral or anterior delivery).



Implant Fixation

- Pre-loaded, multiple (2) anchor delivery in single pass
 - PDO resorbable material
 - Optimized design for both tendon and bone fixation
- Visualization and protection of anchor during delivery
- Simple, quick, single-handed & reproducible operation



LifeNet Exhibit 2012

Embod, et al. v. LifeNet, IPR2025-00248

Page 12

 **MICROBRAID[®]**
Collagen Suture

High Strength Biointegrative Suture



MICROBRAID Overview

Advantages over conventional High-Strength Orthopedic Sutures:

- Biologic: Biostimulative collagen stimulates angiogenesis, promotes new collagen formation and bio-integration.
- Balanced: Controlled degradation of collagen as remodeling occurs, retaining strength of UHMWPE fibers
- Biocompatible: Novel cross-linking has no associated inflammatory response.
- Strength: Comparable strength to conventional UHMWPE products (i.e. FiberWire) for high demand applications such as RCR, M/L Instability, etc.)
- Versatile: RFR 1.5mm & 2.5mm, #2 RND, 2-0 RND




Product attributes are highly tuneable based % and size of collagen fiber



MICROBRAID Bench Data

MICROBRAID

Collagen Coated
UHMWPE (FiberWire)




Human mesenchymal cell proliferation over 14 days

MICROBRAID significantly higher cell attachment capacity compared to collagen coated FiberWire

MICROBRAID facilitates cell attachment and proliferation

Human mesenchymal cell attachment over 24 hours



Focus on Clinical Data Generation

Generate clinical data and long-term evidence

- Use 2021 to create clinical case series data demonstrating value across a breadth of indications:
 - Subscapularis (TSA) – Completed Q4 2021
 - Gluteus Medius Hip – Underway at OSU, Data Q1 2022
 - Foot & Ankle – Protocol in place, Data Q1 2022
- Multi-Ctr Subscapularis Registry underway. 5 sites
- Launch patient registry for Tapestry RC clearance to collect long-term efficacy data which will drive 2024/2025 revenue growth.
- Expand patient registry approach to include Subscapularis (TSA) and Hip Capsule.
- Position ourselves for long-term success with a portfolio of evidence.



Embodly Highlights

Growing and Attractive Market	• Targeting high growth Orthopedics applications for collagen value proposition • Substantially de-risked with 500+ Tapestry Patients • FDA 510(k) Clearance of Tapestry RC System in Q2 2022 • MICROBRAID™ Suture FDA 510(k) clearance in Q1 2023
Novel next-generation regenerative material platform	• Robust IP Portfolio with protection of surgical implants and proprietary components formulation together with state-of-the-art production techniques • 9 US Patents, 18 Patent Families & 27 Pending Applications • Favorable COGs, 80%+ GM and a scalable manufacturing facility • Scalable platform technology across Sports Medicine
Seasoned and experienced team	• Extensive orthopedic, device and biomaterials experience • Successfully lead, commercialized and exited new technologies • Strong Scientific and Clinical Advisor engagement